NCT00160459View on ClinicalTrials.gov

A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Uterine Fibroids

PHASE2CompletedINTERVENTIONAL

Enrollment

129

Participants

Timeline

Start Date

May 31, 2000

Primary Completion Date

July 31, 2001

Study Completion Date

July 31, 2001

Conditions

Leiomyoma

Interventions

DRUG

Asoprisnil

25 mg Tablet, oral Daily for 12 weeks

DRUG

Placebo

Tablet, oral Daily for 12 weeks

DRUG

Asoprisnil

10 mg Tablet, oral Daily for 12 weeks

DRUG

Asoprisnil

5 mg Tablet, oral Daily for 12 weeks

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Abbott

INDUSTRY